Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells.
about
Current and potential treatments for ubiquitous but neglected herpesvirus infectionsIdentification of Viral and Host Proteins That Interact with Murine Gammaherpesvirus 68 Latency-Associated Nuclear Antigen during Lytic Replication: a Role for Hsc70 in Viral ReplicationComplex alternative cytoplasmic protein isoforms of the Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 generated through noncanonical translation initiation.Abrogation of viral interleukin-6 (vIL-6)-induced signaling by intracellular retention and neutralization of vIL-6 with an anti-vIL-6 single-chain antibody selected by phage displayLlama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice.Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replicationCelecoxib Inhibits the Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus through Down-Regulation of RTA Expression by Inhibiting the Activation of p38 MAPK.Molecular approaches towards characterization, monitoring and targeting of viral-associated hematological malignancies.Development of a fluorescence-based assay to screen antiviral drugs against Kaposi's sarcoma associated herpesvirus.Role of IRF4 in IFN-stimulated gene induction and maintenance of Kaposi sarcoma-associated herpesvirus latency in primary effusion lymphoma cellsFrom rabbit antibody repertoires to rabbit monoclonal antibodiesIntracellular antibodies and cancer: new technologies offer therapeutic opportunities.Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen 1 mimics Epstein-Barr virus EBNA1 immune evasion through central repeat domain effects on protein processing.
P2860
Q27023452-BCB9010E-1D89-40B3-AC3F-26D251B97387Q28505713-708F358C-DB2C-4B0C-9F94-98EFB9B65E11Q30535717-F8873BB9-86B2-4773-BED2-6522B34E0A7CQ33254113-633A81EA-6A55-4F04-B15B-1B183E42E5FDQ33393294-EFA5414B-ABC9-45AD-B5E9-D502411C9D4BQ34668776-E4F1C86A-18B1-466C-953C-91A2DD47C18CQ35675995-BC2692C8-4095-4020-BA32-69248E1D1AE3Q36670930-E3471057-820C-4861-B9BA-9EC9E3A42673Q36691938-C0236AF1-81FE-4268-85A8-4517B9EA6093Q37088335-6B30985E-8C0E-4885-8E57-9E11257306F7Q37739483-E51D2E54-0B47-4853-9FC7-8C1275A38A9EQ39864280-CE3CC9CA-1B3C-431E-A0BA-F639EAC8A2DFQ40128647-181BB49A-402A-4A3E-B474-BD2990D5C2A4
P2860
Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells.
description
2005 nî lūn-bûn
@nan
2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Intrabodies targeting the Kapo ...... persistence in lymphoma cells.
@ast
Intrabodies targeting the Kapo ...... persistence in lymphoma cells.
@en
type
label
Intrabodies targeting the Kapo ...... persistence in lymphoma cells.
@ast
Intrabodies targeting the Kapo ...... persistence in lymphoma cells.
@en
prefLabel
Intrabodies targeting the Kapo ...... persistence in lymphoma cells.
@ast
Intrabodies targeting the Kapo ...... persistence in lymphoma cells.
@en
P2860
P50
P1433
P1476
Intrabodies targeting the Kapo ...... persistence in lymphoma cells
@en
P2093
Carlos F Barbas
Chris Collins
P2860
P304
P356
10.1182/BLOOD-2005-04-1627
P407
P577
2005-08-09T00:00:00Z